GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » 3-Year ROIIC %

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) 3-Year ROIIC % : 11.76% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % for the quarter that ended in Dec. 2023 was 11.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % or its related term are showing as below:

HKSE:02348's 3-Year ROIIC % is ranked better than
64.66% of 999 companies
in the Drug Manufacturers industry
Industry Median: 0.92 vs HKSE:02348: 11.76

Dawnrays Pharmaceutical (Holdings) 3-Year ROIIC % Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) 3-Year ROIIC % Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.76 -6.48 0.98 12.74 11.76

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 12.74 - 11.76 -

Competitive Comparison of Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % falls into.



Dawnrays Pharmaceutical (Holdings) 3-Year ROIIC % Calculation

Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( 367.7033534 (Dec. 2023) - 318.2085237 (Dec. 2020) )/( 2352.103 (Dec. 2023) - 1931.153 (Dec. 2020) )
=49.4948297/420.95
=11.76%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Dawnrays Pharmaceutical (Holdings) 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Li Kei Ling
Hung Yung Lai
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited
Li Tung Ming
Fmr Llc 2201 Interest of corporation controlled by you

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines